How could emerging data on novel immuno-oncology (IO) strategies change your approach to therapy?
This educational series examines the current role of immunotherapy in gastric cancers and explores the future direction of IO therapy in treatment. Our globally renowned experts provide an update on advances to care that you can apply to your practice today. They also review National Comprehensive Cancer Network guidelines pertaining to patients with MSI-H/dMMR or HER2+ colorectal cancer; gastric, esophageal, and gastroesophageal junction cancers; and advanced hepatocellular carcinoma.
In Partnership with: